Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10887038 | 0.88 | ALDH1A1 (0.52) | ALDH1A1CASP1CA2 | |
| SCHEMBL6022077 | 0.88 | ALDH1A1 (0.52) | ALDH1A1CASP1CA2 | |
| SCHEMBL3919350 | 0.88 | ALDH1A1 (0.52) | ALDH1A1CASP1CA2 | |
| SCHEMBL2966988 | 0.88 | ALDH1A1 (0.63) | ALDH1A1CASP1 | |
| SCHEMBL10884777 | 0.88 | ALDH1A1 (0.63) | ALDH1A1CASP1 | |
| SCHEMBL2977396 | 0.88 | ALDH1A1 (0.63) | ALDH1A1CASP1 | |
| SCHEMBL19732325 | 0.87 | ALDH1A1 (0.51) | ALDH1A1CASP1CA2ITGB1ITGA4 | |
| SCHEMBL29908104 | 0.87 | TGM2 (0.52) | ALDH1A1CASP1CA2GPR34 | |
| SCHEMBL29908127 | 0.84 | MAPT (0.48) | ALDH1A1CASP1 | |
| SCHEMBL7140663 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CASP1ITGB1ITGA4GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994168-B2 | Hexahydro-pyrazino[1,2-A]pyrimidine-4,7-dione derivatives substituted with amino acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7652007-B2 | Obesity, type II diabetes; such as 6-(4-Chlorobenzyl)-1-(2,4-dichlorobenzenesulfonyl)-8-isopropylhexahydropyrazino[1,2-a]pyrimidine-4,7-dione | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-01-26 | — | — | US | disclosed |
| EP-1597259-B1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO 1,2-A PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-30 | — | — | EP | disclosed |
| US-20070197539-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1799683-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4, 7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006024390-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4, 7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | WO | disclosed |
| EP-1597259-A1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO 1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| WO-2004072077-A1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197539-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | TYMP, DPYD, P2RX7 | ALDH1A1 879/4885CASP1 814/4885KMT2A 3945/4885 |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, NUDT1, NT5C2 | ALDH1A1 458/4885CASP1 858/4885KMT2A 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.